Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Milk antibody response after 3rd dose of COVID-19 mRNA vaccine and SARS-CoV-2 breakthrough infection and implications for infant protection

Yarden Golan, Mikias Ilala, Caryl Gay, Soumya Hunagund, Christine Y. Lin, Arianna G. Cassidy, Unurzul Jigmeddagva, Lin Li, Nida Ozarslan, Ifeyinwa V. Asiodu, Nadav Ahituv, Valerie J. Flaherman, Stephanie L. Gaw, Mary Prahl
doi: https://doi.org/10.1101/2022.12.12.22283367
Yarden Golan
1Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, and Institute for Human Genetics, University of California, San Francisco, California, United States of America
Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mikias Ilala
2Department of Pediatrics, University of California, San Francisco, California, United States of America
3Division of Experimental Medicine, Department of Medicine, University of California, San Francisco, California, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Caryl Gay
4Department of Family Health Care Nursing, University of California, San Francisco, California, United States of America
Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Soumya Hunagund
5Division of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco, California, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christine Y. Lin
5Division of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco, California, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arianna G. Cassidy
5Division of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco, California, United States of America
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Unurzul Jigmeddagva
6Center for Reproductive Sciences, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco, California, United States of America
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lin Li
5Division of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco, California, United States of America
6Center for Reproductive Sciences, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco, California, United States of America
M.D., Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nida Ozarslan
5Division of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco, California, United States of America
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ifeyinwa V. Asiodu
4Department of Family Health Care Nursing, University of California, San Francisco, California, United States of America
Ph.D, R.N.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nadav Ahituv
1Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, and Institute for Human Genetics, University of California, San Francisco, California, United States of America
Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Valerie J. Flaherman
2Department of Pediatrics, University of California, San Francisco, California, United States of America
M.D., M.P.H.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephanie L. Gaw
5Division of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco, California, United States of America
6Center for Reproductive Sciences, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco, California, United States of America
M.D., Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Stephanie.Gaw@ucsf.edu mary.prahl@ucsf.edu
Mary Prahl
2Department of Pediatrics, University of California, San Francisco, California, United States of America
7Division of Pediatric Infectious Diseases and Global Health, University of California, San Francisco, California, United States of America
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Stephanie.Gaw@ucsf.edu mary.prahl@ucsf.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Anti-SARS-CoV-2 antibodies have been found in human-milk after COVID-19 infection and vaccination. However, little is known about their persistence in milk after booster vaccination and breakthrough infection. In this study, human-milk, saliva and blood samples were collected from 33 lactating individuals before and after mRNA-based vaccination and COVID-19 breakthrough infections. Antibody levels were measured using ELISA and symptoms were assessed using questionnaires. Evaluation of maternal and infant symptomatology revealed that infected mothers reported more symptoms than vaccinated mothers. We found that after vaccination, human-milk anti-SARS-CoV-2 antibodies persisted for up to 8 months. In addition, distinct patterns of human milk IgA and IgG production we observed after breakthrough infection compared to 3-dose vaccination series alone, indicating a differential central and mucosal immune profiles in hybrid compared with vaccine-induced immunity. To investigate passively-derived milk antibody protection in infants, we examined the persistence of these antibodies in infant saliva after breastfeeding. We found that IgA was more abundant in infant saliva compared to IgG and persist in infant saliva longer after feeding. Our results delineate the differences in milk antibody response to vaccination as compared to breakthrough infection and emphasize the importance of improving the secretion of IgA antibodies to human milk after vaccination to improve the protection of breastfeeding infants.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

Y.G. was supported by the Weizmann Institute of Science - National Postdoctoral Award Program for Advancing Women in Science, and of the Human Frontiers in Science Program (HFSP). M.P. was supported by the National Institutes of Health (NIAID K23AI127886), the Marino Family Foundation, and UCSF REAC award. S.L.G. was supported by the National Institutes of Health (NIAID K08AI141728).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The institutional review board of the University of California, San Francisco, approved the study (#21-33621). Written informed consent was obtained from all study volunteers as part of the COVID-19 Vaccine in Pregnancy and Lactation (COVIPAL) cohort study.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Conflict of interest: The authors have declared that no conflict of interest exists.

  • Funding: Y.G. was supported by the Weizmann Institute of Science -National Postdoctoral Award Program for Advancing Women in Science, and of the Human Frontiers in Science Program (HFSP). M.P. was supported by the National Institutes of Health (NIAID K23AI127886), the Marino Family Foundation, and UCSF REAC award. S.L.G. was supported by the National Institutes of Health (NIAID K08AI141728).

Data Availability

All data produced in the present study are available upon reasonable request to the authors

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted December 14, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Milk antibody response after 3rd dose of COVID-19 mRNA vaccine and SARS-CoV-2 breakthrough infection and implications for infant protection
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Milk antibody response after 3rd dose of COVID-19 mRNA vaccine and SARS-CoV-2 breakthrough infection and implications for infant protection
Yarden Golan, Mikias Ilala, Caryl Gay, Soumya Hunagund, Christine Y. Lin, Arianna G. Cassidy, Unurzul Jigmeddagva, Lin Li, Nida Ozarslan, Ifeyinwa V. Asiodu, Nadav Ahituv, Valerie J. Flaherman, Stephanie L. Gaw, Mary Prahl
medRxiv 2022.12.12.22283367; doi: https://doi.org/10.1101/2022.12.12.22283367
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Milk antibody response after 3rd dose of COVID-19 mRNA vaccine and SARS-CoV-2 breakthrough infection and implications for infant protection
Yarden Golan, Mikias Ilala, Caryl Gay, Soumya Hunagund, Christine Y. Lin, Arianna G. Cassidy, Unurzul Jigmeddagva, Lin Li, Nida Ozarslan, Ifeyinwa V. Asiodu, Nadav Ahituv, Valerie J. Flaherman, Stephanie L. Gaw, Mary Prahl
medRxiv 2022.12.12.22283367; doi: https://doi.org/10.1101/2022.12.12.22283367

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (269)
  • Allergy and Immunology (549)
  • Anesthesia (135)
  • Cardiovascular Medicine (1748)
  • Dentistry and Oral Medicine (238)
  • Dermatology (172)
  • Emergency Medicine (310)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (653)
  • Epidemiology (10785)
  • Forensic Medicine (8)
  • Gastroenterology (584)
  • Genetic and Genomic Medicine (2935)
  • Geriatric Medicine (286)
  • Health Economics (531)
  • Health Informatics (1919)
  • Health Policy (833)
  • Health Systems and Quality Improvement (743)
  • Hematology (290)
  • HIV/AIDS (627)
  • Infectious Diseases (except HIV/AIDS) (12500)
  • Intensive Care and Critical Care Medicine (684)
  • Medical Education (299)
  • Medical Ethics (86)
  • Nephrology (321)
  • Neurology (2783)
  • Nursing (150)
  • Nutrition (431)
  • Obstetrics and Gynecology (555)
  • Occupational and Environmental Health (597)
  • Oncology (1457)
  • Ophthalmology (441)
  • Orthopedics (172)
  • Otolaryngology (255)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (380)
  • Pediatrics (865)
  • Pharmacology and Therapeutics (362)
  • Primary Care Research (334)
  • Psychiatry and Clinical Psychology (2633)
  • Public and Global Health (5341)
  • Radiology and Imaging (1004)
  • Rehabilitation Medicine and Physical Therapy (595)
  • Respiratory Medicine (724)
  • Rheumatology (329)
  • Sexual and Reproductive Health (289)
  • Sports Medicine (278)
  • Surgery (327)
  • Toxicology (47)
  • Transplantation (149)
  • Urology (125)